MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2022 International Congress

    Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3: a randomized, double-blind, sham-controlled trial

    R. Maas, S. Teerenstra, I. Toni, T. Klockgether, D. Schutter, B. Vande Warrenburg (Nijmegen, Netherlands)

    Objective: To investigate if a 2-week regimen comprising daily sessions of cerebellar anodal transcranial direct current stimulation (tDCS) 1) diminishes ataxia and non-motor symptom severity…
  • 2022 International Congress

    Therapies, Research Funding and Racial Diversity in Cerebellar Ataxia: A Systematic Review of the Literature

    C. Kingsbury, S. Ghanekar, Y. Huang, T. Ashizawa, S. Kuo, C. Gooch, T. Zesiewicz (Tampa, USA)

    Objective: To understand the scope of clinical research in cerebellar ataxia by performing a systematic review of controlled clinical trials over the past 50 years,…
  • 2022 International Congress

    Isolated ZIC4 antibody associated paraneoplastic cerebellar degeneration

    A. Agarwal, A. Garg, A. Srivastava (New Delhi, India)

    Objective: Anti-ZIC4 antibodies have recently been associated with paraneoplastic cerebellar degeneration (PCD) and are usually associated with small cell carcinoma lung. However, most of the…
  • 2022 International Congress

    Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia

    M. Baile, D. Schecter, A. Miller, T. Galas, N. Scherer, R. Chen, N. Ruiz, D. Bettoun (Philadelphia, USA)

    Objective: To identify genetic disease and efficacy markers for Friedreich’s ataxia (FRDA) Background: FRDA is a genetic disease caused by decreased expression of the mitochondrial…
  • 2022 International Congress

    Leading Therapeutic Molecules Target Transcription Factors Binding to Repressor Region in FXN Gene

    V. Swarup, H. Singh, D. Gupta, I. Singh, A. Srivastava (New Delhi, India)

    Objective: To investigate interactions of transcription factors (TFs) binding to repressor region located upstream to FXN gene with leading therapeutic molecules. Background: Low levels of…
  • MDS Virtual Congress 2021

    Cerebellar bioenergetic depletion following ubiquinol supplementation in a patient with COQ8A-related ataxia

    J. Prasuhn, M. Göttlich, B. Ebeling, C. Bodemann, S. Großer, I. Wellach, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)

    Objective: To non-invasively map the individual treatment response in a patient with COQ8A-related ataxia following coenzyme Q10 supplementation. Background: Primary coenzyme Q10 (CoQ10) deficiency is…
  • MDS Virtual Congress 2020

    Effects of deep transcranial magnetic stimulation of the cerebellum on cerebellar ataxias: A randomized, double-blind, cross-over clinical trial

    C. França, D. de Andrade, V. Silva, R. Galhardoni, E. Barbosa, M. Teixeira, R. Cury (Sao Paulo, Brazil)

    Objective: To investigate whether cerebellar deep repetitive transcranial magnetic stimulation (d-rTMS) can improve ataxic symptoms when compared to sham stimulation. Background: Cerebellar ataxia remains a…
  • MDS Virtual Congress 2020

    A randomized, sham-controlled, crossover trial on Cerebello-Spinal Transcranial pulsed current stimulation (tPCS) in Ataxia

    J. Ganguly, D. Kulshreshtha, S. Soltani, Y. Krishnasamy Tamilselvam, O. Samotus, D. Aur, M. Jog (London, ON, Canada)

    Objective: Patients of degenerative cerebellar ataxia present with slurring of speech, imbalance during walking and problem of co-ordination in limbs.  Currently no effective treatment is…
  • MDS Virtual Congress 2020

    Plasma biomarker quantification in SCA3 using the Neurology 4-PLEX A kit and the Simoa technology

    H. Garcia-Moreno, G. Thomas-Black, A. Heslegrave, H. Zetterberg, P. Giunti (London, United Kingdom)

    Objective: We present the results of plasma biomarker quantification in a cohort of spinocerebellar ataxia type-3 (SCA3) carriers using a Simoa assay. Background: Development of…
  • MDS Virtual Congress 2020

    Amantadine Therapy for Ataxia Management in Patients with Spinocerebellar Ataxia Type 7

    L. Pesantez Pacheco, N. Thakur (Houston, TX, USA)

    Objective: To report the therapeutic effects of amantadine in a patient with Spinocerebellar ataxia type 7 (SCA7) Background: Spinocerebellar ataxia type 7 is a rare…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley